Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
BNT-164 by BioNTech for Tuberculosis: Likelihood of Approval
BNT-164 is under clinical development by BioNTech and currently in Phase II for Tuberculosis. According to GlobalData, Phase II drugs...